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Interleukin-15irus (SIV) infection of rhesus macaques is a valuable animal model for human
immunodeﬁciency virus (HIV)-1 vaccine development. Our laboratory recently described the immunogeni-
city and limited efﬁcacy of a vif-deleted SIVmac239 proviral DNA (SIV/CMVΔvif) vaccine. The current report
characterizes immunogenicity and efﬁcacy for the SIV/CMVΔvif proviral DNA vaccine when co-inoculated
with an optimized rhesus interleukin (rIL)-15 expression plasmid. Macaques co-inoculated with rIL-15 and
SIV/CMVΔvif proviral plasmids showed signiﬁcantly improved SIV-speciﬁc CD8 T cell immunity character-
ized by increased IFN-γ ELISPOT and polyfunctional CD8 T cell responses. Furthermore, these animals
demonstrated a sustained suppression of plasma virus loads after multiple low dose vaginal challenges with
pathogenic SIVmac251. Importantly, SIV-speciﬁc cellular responses were greater in immunized animals
compared to unvaccinated controls during the initial 12 weeks after challenge. Taken together, these ﬁndings
support the use of IL-15 as an adjuvant in prophylactic anti-HIV vaccine strategies.
© 2009 Elsevier Inc. All rights reserved.IntroductionDevelopment of an efﬁcacious vaccine against human immuno-
deﬁciency virus (HIV)-1 is a major priority for control of the AIDS
pandemic. Simian immunodeﬁciency virus (SIV) and SIV/HIV (SHIV)
infections of rhesus macaques have provided highly relevant animal
models for HIV-1 vaccine development and valuable insights into the
feasibility of developing a safe and effective vaccine against human
AIDS. Due to difﬁculties in generating vaccines capable of eliciting
high titers of broadly reactive neutralizing antibodies, efforts have
focused on vaccines designed to elicit strong antigen-speciﬁc T cell
responses that will signiﬁcantly suppress virus loads and improve host
survival. Recent accomplishments in vaccine development derived
from these animal models have resulted in a focus on prime-boost
strategies that incorporate priming immunization with viral antigen
expression plasmids, followed by boosting with viral immunogens
expressed from a viral vaccine vector (Letvin, 2006). The most).
l rights reserved.extensively tested viral vectors include replicating and nonreplicating
adenoviruses (Ad), with non-replicating Ad serotype 5 (Ad5) as the
focus of more recent vaccine studies in both macaques and human
clinical trials (Hokey and Weiner, 2006; Letvin, 2007; Robert-Guroff,
2007). However, concerns with this and other viral vectors are based
on issues of pre-existing host immunity to a particular viral vector,
leading to diminished and insufﬁcient expression of the inserted
immunogen and vaccine efﬁcacy. These concerns have largely been
validated with the recent failure of the Merck STEP trial whereby pre-
existing immunity to the Ad vector not only down-modulated the HIV
insert response, but also modulated the response to facilitate, rather
than prevent infection for particular populations (Priddy et al., 2008).
These results emphasize the need for continued exploration of other
unique vaccine approaches that may include novel DNA vaccines and
immunomodulators, or combinations thereof.
Vaccine approaches based on plasmid DNA only, or DNA plasmid
priming following by a protein boost, while promising in rodents, have
proven relatively inefﬁcient in larger animal models including
primates (Hokey and Weiner, 2006; Ulmer et al., 2000). However,
similar vaccine approaches that include co-administration of DNA
Fig. 1. Production of rIL-15 from an optimized expression plasmid. Expression plasmids
designated pNDRRm-IL-15 and pNDgmsRRm-IL-15, were constructed as described in
Materials and methods and were distinguished by their leader sequences. Cell culture
supernatants were harvested at two, four, and six days from either COS-7 or 293T cells,
after transfection with a rIL-15 expression plasmid and tested for IL-15 concentrations
by a commercial human IL-15 antigen-capture ELISA (Invitrogen, Biosource) as
described in Materials and methods. Error bars represent standard deviation.
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plasmids, have demonstrated marked improvement of vaccine-
induced immune responses when tested in SIV and SHIV animal
models. Cytokines that increase clonal expansion of antigen-speciﬁc T
cells, including the common γ chain (γc) cytokine interleukin (IL)-15,
or IL-12, have been particularly promising as adjuvants for prophy-
lactic DNA vaccines and show some promise as potent immunomo-
dulators when delivered in the optimal setting (Calarota and Weiner,
2004; Lori et al., 2006). IL-15 is a pleiotropic cytokine that can affect
both innate and adaptive immune responses and has shown particular
promise as an adjuvant for cancer vaccine design (Waldmann, 2006).
IL-15 shares some properties with IL-2, including potent stimulation
of proliferation of activated peripheral blood T cells, natural killer (NK)
cells, and NKT cells (Becker et al., 2002; Oh et al., 2003; Surh and
Sprent, 2002;Waldmann et al., 2001). IL-15 is also a potent activator of
the innate immune system throughmechanisms that are distinct from
induction of NK cells and include promotion of dendritic cell induction
and maturation. Moreover, IL-15 used either as a therapeutic or
vaccine adjuvant, was shown to enhance the proliferation and
longevity of memory CD8 or CD4 T cells through up-regulation of
anti-apoptotic molecules (Boyer et al., 2007; Kutzler et al., 2005; Lin et
al., 2005; Oh et al., 2008; Picker et al., 2006; Waldmann et al., 2001;
Zhang et al., 2006). Overall, these properties of IL-15 provide strong
support for further investigation of this cytokine as an adjuvant for
HIV DNA vaccine approaches.
A recent report by our laboratory described the investigation of a
vif-deleted SIVmac239 provirus as an attenuated proviral DNA
vaccine. Inoculation of rhesus macaques with this vif-deleted provirus
induced strong SIV-speciﬁc T cell proliferative responses and low
antibody titers in the face of an undetectable infection (Sparger et al.,
2008). Transient suppression of pathogenic SIVmac251 was observed
in vaccinated animals early after vaginal challenge; however differ-
ences in virus loads between vaccinated and unvaccinated animals
were not sustained. However, despite induction of strong T cell
proliferative responses, SIV-speciﬁc CD8 T cell responses elicited by
this DNA vaccine were either very weak or absent in vaccinated
animals. Based on these observations, a second investigation was
designed to test the immunogenicity and efﬁcacy of an immunization
approach that included this vif-deleted SIVmac239 provirus plasmid
and an expression plasmid optimized for rhesus macaque IL-15, as a
combination DNA vaccine. This report describes adjuvant effects that
were conferred by IL-15 for this DNA vaccine, and that included
increased frequencies of SIV-speciﬁc CD8 T cell responses and
induction of antigen-speciﬁc polyfunctional CD8 T cell responses.
Furthermore, animals vaccinated with proviral DNA and an IL-15
expression plasmid exhibited signiﬁcantly lower virus loads compared
to unvaccinated controls, during acute and chronic phases of infection
after challenge with pathogenic SIVmac251.
Results
Comparison of IL-15 expression from two different rIL-15 plasmids
The objective of this vaccine study was to test for enhanced
immunogenicity and for efﬁcacy conferred by an IL-15 expression
plasmid to a previously described vif-deleted SIVmac239 proviral DNA
vaccine (SIV/CMVΔvif) (Sparger et al., 2008). Therefore, construction
of a rhesus macaque IL-15 (rIL-15) expression plasmid with optimal
activity was critical for accomplishing this goal. Measurements of
soluble rIL-15 generated by transfection of T293 and COS-7 cells with
pNDgmsRRm-IL-15 containing the Mamu IL-15 coding sequence with
the granulocyte macrophage-colony stimulating factor (GM-CSF)
leader revealed a 20 to 300-fold increase at every time point tested
in transfected-cell culture supernatants, when compared to produc-
tion after transfection with pND RRm-IL-15 encoding Mamu IL-15
coding sequence with the native IL-15 leader (Fig. 1). A recent reportdescribing optimized rIL-15 expression plasmids, revealed a similar
magnitude of increased rIL-15 expression using the same GM-CSF
leader upstream of the native rIL-15 signal peptide in a different
plasmid backbone, although this report revealed a slightly higher
expression with use of the tissue plasminogen activator (TPA) signal
peptide (Jalah et al., 2007). Furthermore, evaluation of biological
activity of the released cytokine using the IL-2/15 dependent HT-2 cell
line (Villinger et al., 1995) indicated that secreted cytokine was
biologically active when compared to recombinant IL-15 (data not
shown). These data validated use of the pNDgmsRRm-IL-15 expres-
sion plasmid for delivery of rIL-15 as a vaccine cytokine adjuvant.
Induction of SIV-speciﬁc cellular immune responses by co-immunization
with SIV/CMVΔvif and pNDgmsRRm-IL-15 plasmids
Virus-speciﬁc CD8 T cell responses have been shown to be critical
for host control of plasma virus loads for both SIV and HIV-1 infections
(Jin et al., 1999;Musey et al.,1997; Ogg et al., 1998; Schmitz et al.,1999;
Yasutomi et al., 1993). Accordingly, a recombinant vaccinia-based
interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) previously
shown to measure predominantly CD8 responses (Larsson et al., 1999)
was utilized to examine vaccine-induced cellular responses speciﬁc to
four different SIV antigens (Gag, Env, Nef, and Pol). IFN-γ ELISPOT
responses were observed in PBMC from some, but not all animals, by
four weeks after a priming vaccination with the SIV/CMVΔvif plus IL-
15 DNA vaccine (Fig. 2). ELISPOT responses to SIV antigens were
moderately improved by the ﬁrst booster immunization, particularly
responses to SIV Gag. IFN-γ ELISPOT responses were further
augmented in a majority of the animals for all four SIV antigens,
when tested at either two weeks, or ten weeks after a second booster
immunization with vaccine plasmids. Vaccine-induced IFN-γ ELISPOT
responses were variable over time, but were greatest for SIV Gag, Env,
and Nef, with lower responses observed for SIV Pol for time points
prior to challenge. Pair-wise comparisons of mean responses to either
Gag, Env, and Nef with responses to Pol revealed signiﬁcant
differences with P values ranging from 0.002 to 0.046 for earlier
time points after priming immunization. However, IFN-γ ELISPOT
responses tested on the day of challenge were comparable for all four
SIV antigens.
Proliferation of PBMC in response to stimulation with inactivated
SIV preparations provided another measure of antiviral cellular
responses that predominantly reﬂects CD4 activity, but may also
Fig. 3. SIV-speciﬁc T cell proliferative and antiviral antibody responses elicited by co-
immunization with SIV/CMVΔvif plasmid DNA and pNDgmsRRm-IL-15 plasmid DNA.
Virus-speciﬁc T cell proliferative responses directed to puriﬁed inactivated SIV were
measured in PBMC harvested from macaques at various time points after priming
immunization. Values for the highest SI to either 12.5 or 125 ng of SIV p27Gag are
shown (A). A SI of 2.5 or greater was considered positive. Reciprocal endpoint titers for
plasma antibodies against native SIV Env were measured using a ConA ELISA with
reciprocal log dilution values greater than 100 representing positive titers (B). Arrows
positioned at 8 and 20 weeks after priming immunization denoted time points of
booster vaccine inoculations.
Fig. 2. SIV-speciﬁc IFN-γ ELISPOT responses elicited by co-immunization with SIV/
CMVΔvif and pNDgmsRRm-IL-15 plasmid DNA. SIV-speciﬁc IFN-γ ELISPOT responses
were assayed on cryopreserved PBMC harvested from animals at various time points
after vaccination. Immune responses to individual SIVmac239 proteins were measured
using recombinant vaccinia viruses expressing either SIV Gag, Env, Nef or Pol, with
protocols described in Materials and methods. Values less than 50 spot-forming
colonies (SFC) per 106 PBMC were considered nonspeciﬁc for this assay. Arrows
positioned at 8 and 20 weeks after priming immunization denoted time points of
booster vaccine inoculations.
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sured in PBMC were observed for all animals at multiple time points
following immunization with the SIV/CMVΔvif plus IL-15 DNA
vaccine (Fig. 3A). Similar to IFN-γ ELISPOT responses, SIV-speciﬁc T
cell proliferative responses were quite variable between animals and
stimulation indices (SI) ranged from 2.5 to 35 over different timepoints. In general, proliferative responses were quite robust with SI
of 15 or greater observed for all animals for at least one time point,
and for at least two time points for ﬁve of six immunized macaques.
Booster immunizations also resulted in enhanced antigen-speciﬁc
proliferative responses for all six vaccines. Taken together, these
results revealed a strong cellular response to this proviral DNA
vaccine that included a rIL-15 plasmid. Notably, inoculation of
macaques with the highly attenuated vif-deleted provirus and rIL-15
plasmids did not result in detectable infection by assay of PBMC for
proviral DNA by real-time PCR, similar to a previous inoculation
study with SIV vif-deleted provirus alone (Sparger et al., 2008) (data
not shown).
SIV-speciﬁc antibody responses after immunization with SIV/CMVΔvif
proviral DNA and rIL-15 plasmids
Antibody responses have proven to be very low or absent in
animals inoculated with vif-deleted lentiviruses delivered either as a
provirus plasmid, or as a virus preparation (Desrosiers et al., 1998;
Gupta et al., 2007; Harmache et al., 1996; Lockridge et al., 2000;
Sparger et al., 2008). For this reason, a sensitive concanavalin-A (Con-
A) ELISA was utilized for detection of antiviral antibody induction by
the SIV/CMVΔvif plus IL-15 DNA vaccine. Low antibody titers to native
SIV Env were detected by 8 weeks after priming immunization in two
of six animals (Fig. 3B). All animals were positive for Env antibody
Table 1
Detection of SIV antibody by ELISA
Animal
no.
Weeks after priming immunization
0 8⁎ 20⁎ 22 24 30
32180 − − − + + +
31541 − − + + + +
31063 − − + + + +
30889 − − − + + −
30559 − − + + + +
29551 − − − − − −
⁎ Time points for booster immunization.
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increased again after a second booster immunization with the SIV/
CMVΔvif plus IL-15 DNA vaccine. SIV-speciﬁc antibody was not
detected by a commercial ELISA after priming immunization
(Table 1). However, antiviral antibodies were detected by this ELISA
in three out of six animals after the ﬁrst booster, and in ﬁve out of six
after the second booster immunization. These ﬁndings of low antiviral
antibody induction were consistent with previous reports describing
inoculation of animals with lentiviruses encoding mutations in vif,
including our previous study testing SIV/CMVΔvif as a single modality
DNA vaccine (Sparger et al., 2008). These results also revealed that co-
inoculation of rIL-15 expression plasmid did not result in a signiﬁcant
improvement of humoral responses over those induced by immuniza-
tion of SIV/CMVΔvif alone (Sparger et al., 2008), at least as measured
by these standard antibody assays.Fig. 4. Plasma virus loads after multiple low dose IVAG challenge of vaccinated and unvaccina
of plasma, was determined after SIVmac251 challenge by a real-time RT-PCR assay for SIV gag
measured at 12 weeks after initial challenge (C) are compared between viremic vaccinat
vaccinated animal excluded from the analysis. Geometric means for plasma RNA loads for all v
shown (D). In a different analysis, a nonlinear mixed-effects model based on an exponential f
ﬁrst observation of peak plasma viral RNA, to provide mean virus load curves for vaccina
uninfected vaccinated animal excluded from the analysis.Effects of vaccination with SIV/CMVΔvif proviral DNA and rIL-15
plasmids on plasma virus load after multiple low dose IVAG challenge
with SIVmac251
Efﬁcacy of the SIV/CMVΔvif plus IL-15 DNA vaccine was tested by
challenge with SIVmac251 by the vaginal route using a multiple low
dose protocol as previously described (Ma et al., 2004). This protocol
consisted of weekly intravaginal (IVAG) administrations of 103 tissue
culture infectious dose 50 (TCID50) of SIVmac251 to each macaque
until that animal became positive for SIV RNA in plasma for two
consecutive weeks by a quantitative real-time reverse transcriptase
(RT) TaqMan PCR assay. This challenge protocol was considered a
more biologically relevant approach for challenge with the highly
pathogenic SIVmac251. Salient ﬁndings regarding virus loads after
multiple low dose IVAG challenge study included the following
observations. Five of six unvaccinated control macaques were positive
for plasma viral RNA between 1 to 3 weeks after initial challenge, with
peak virus loads of 107 RNA copies per ml or higher (Fig. 4A). Peak
virus loads and kinetics were very similar for all unvaccinated
macaques with the exception of animal 32144 that required six
weeks of challenge before demonstrating plasma viremia with a peak
virus load of 8×105 RNA copies per ml. This animal subsequently
controlled plasma virus load to undetectable levels in plasma by
twelve weeks after the initial challenge inoculation. Importantly,
plasma virus loads were maintained below 105 RNA copies per ml for
four out of the six vaccinated animals, compared to two out of six
unvaccinated controls up to 25 weeks after the initial challengeted macaques with SIVmac251. Plasma virus loads represented as SIV RNA copies per ml
RNA for vaccinated and unvaccinatedmacaques (A). Peak virus loads (B) and virus loads
ed and unvaccinated macaques using the Mann–Whitney U test with the uninfected
accinated and control macaques over time after the initial challenge inoculation are also
unctionwas ﬁtted to log RNA values, with plasma RNA concentrations recorded from the
ted and unvaccinated macaques through the duration of the study (E), also with the
113R.A. Dubie et al. / Virology 386 (2009) 109–121inoculation (Fig. 4A). A comparison of mean peak virus load for
viremic vaccinees (5.03×105 RNA copies per ml) and unvaccinated
animals (1.75×107 RNA copies per ml) during acute infection revealed
a signiﬁcant difference based on the Mann–Whitney U test (P=0.004)
(Fig. 4B). Mean virus loads for viremic vaccinated animals remained
lower compared to unvaccinated controls at 12 weeks after the initial
challenge time point (P=0.047) (Fig. 4C). Furthermore, a comparison
of geometric means for virus loads revealed a reduction of loads by 1
log or more for vaccinated animals compared to controls through a 25
week period after the initial challenge inoculation (Fig. 4D). In a
separate analysis, a nonlinear mixed-effects model based on an
exponential function was ﬁtted to log plasma RNA values, with values
recorded from ﬁrst observation of peak RNA, to generate plasma virus
load curves for comparison of vaccinated and unvaccinated animals.
This second analysis also revealed a signiﬁcantly lower mean peak
plasma virus load for vaccines (P=0.001) during acute infection and
during the early set point period of infection (up to 16 weeks after
peak viremia) (P=0.022), when compared to the virus load curve
derived for unvaccinated controls (data not shown). A comparison of
mean plasma virus load curves using a similar analysis that included
later time points after challenge (20–36 weeks post infection), also
revealed a lower mean plasma virus load for viremic vaccines,
although the difference between curves for vaccinated and control
animals was not signiﬁcant when later time points were included
(P=0.07) (Fig. 4E). It is important to note that these analyses included
only the viremic vaccinees (5/6) and unvaccinated controls (6/6).
Interestingly, one vaccinated animal (31541) remained negative for
plasma virus during the entire duration of the study, with the
exception of one time point (8 weeks after initial challenge) where a
virus load of 60 viral RNA copies per ml was detected.
Effects of vaccination on peripheral blood CD4 T cell concentrations after
challenge with SIVmac251
Although co-immunizationwith SIV/CMVΔvif and pNDgmsRRm-IL-
15 plasmids resulted in a signiﬁcant suppression of plasma virus loads
after challenge, infection of vaccinated animals resulted in a general
decrease of peripheral blood CD4 T cells during the acute phase of
infection, even compared to infected unvaccinated controls (Figs. 5A, B).
In fact, mean values for CD4 T cell percentages measured for vaccinated
animals at four and eight weeks after initial challenge inoculationswere
moderately but signiﬁcantly lower (P=0.02 and P=0.004, respectively)
than mean values measured for unvaccinated controls (Fig. 5C). The
reason for this decrease remains to be fully elucidated, but may rely on
increased elimination of CCR5+ CD4 T cell targets in the periphery, orFig. 5. Quantitation of CD4 Tcell percentages after challengewith SIVmac251. Peripheral bloo
macaques after SIVmac251 challenge. Mean values with standard error for CD4 T cell per
positioned over values at 4 and 8 weeks after challenge indicate a signiﬁcant difference bet
comparison using a Mann–Whitney U test.increased emigrationof CD4Tcells into the tissueas a consequence of IL-
15 (Picker et al., 2006). By ten weeks after initial challenge inoculation,
CD4 T cell percentages for vaccinated and unvaccinated controls were
comparable. Values for CD4 T cell percentages remained stable for
vaccinated animals, and were comparable to those measured for
unvaccinated controls for the duration of the study.
SIV-speciﬁc CD8 T cell responses after challenge
IFN-γ ELISPOT responses to all four viral antigens measured for
vaccinated animals showed an immediate decline at two weeks after
the initial challenge (Fig. 6A). This decline was observed for ﬁve of the
six vaccinated animals, includingmacaque 31541which failed to show
evidence of infection. However, low tomoderate responses to SIV Gag,
Env, and Nef were again evident by 8 to 20 weeks after the initial
challenge inoculation, for ﬁve of the six vaccinated macaques. In
contrast, unvaccinated controls demonstrated very low to undetect-
able IFN-γ ELISPOT responses to all four SIV antigens during this same
time frame (Fig. 6B). Notably, mean IFN-γ ELISPOT responses to SIV
Gag, Env, and Nef for vaccinated animals were signiﬁcantly greater
than those measured for unvaccinated controls for multiple time
points within 20 weeks after challenge (Fig. 6C). A direct correlation
between IFN-γ ELISPOT responses on the day of challenge and control
of virus load after challenge was not apparent for individual vaccines.
To examine an association between IFN-γ ELISPOT responses and
emergence of plasma viremia after challenge, plasma virus loads were
plotted against SIV Gag IFN-γ ELISPOT values over time after challenge
(Supplemental Fig. 1). Interestingly, an association between virus
loads and IFN-γ ELISPOT responses was suggested for ﬁve of six
vaccinated macaques, including the vaccinated animal for which
plasma viral RNA was detected at a very low concentration for one
time point only for the duration of this vaccine study. This particular
animal (31541) demonstrated IFN-γ ELISPOT responses for multiple
time points after challenge despite an undetectable virus load.
However, IFN-γ ELISPOT responses were not observed for another
vaccinees that displayed signiﬁcant suppression of plasma viral RNA
concentrations (29551) over time. Higher virus loads were observed
with very low or undectectable IFN-γ ELISPOT responses for four
unvaccinated controls. In contrast, moderate IFN-γ ELISPOT responses
were observed for one control animal (32144), which suppressed
plasma virus to concentrations below the limit of detection of the real-
time PCR assay. A sixth control animal (32792) that also controlled
plasma virus loads to approximately 104 SIV RNA copies per ml,
displayed moderate, although transient IFN-γ ELISPOT responses after
challenge. Although these ﬁndings suggested a possible relationshipd CD4 T cell percentages were calculated for vaccinated (A) and unvaccinated control (B)
centages over time challenge are shown for both groups of animals (C). Asterisks (⁎)
ween vaccinated and SIV-infected unvaccinated controls as determined by a pair-wise
Fig. 6. IFN-γ ELISPOT responses in animals after challenge with SIVmac251. Virus-speciﬁc IFN-γ ELISPOT responses were measured for vaccinated (A) and unvaccinated (B) animals
over time after the initial challenge inoculation. Mean values for SFC with standard error over time after challenge are shown for both groups of animals (C). Asterisks (⁎) positioned
over values indicate a signiﬁcant difference between vaccinated and SIV-infected unvaccinated controls as determined by a pair-wise comparison using a Mann–Whitney U test.
114 R.A. Dubie et al. / Virology 386 (2009) 109–121between virus load and IFN-γ ELISPOT responses, a statistically
signiﬁcant relationship between IFN-γ ELISPOT responses and virus
loads after challenge was not evident (R=−0.2476; P=0.06).
SIV-speciﬁc T cell proliferative responses after challenge
SIV-speciﬁc proliferative responses were variable for vaccinated
animals, but were observed for all vaccines during early time points
following the initial challenge inoculationwith pathogenic SIVmac251
(Fig. 7A). Although the magnitude of proliferation responses declined
over a 16 week time period after challenge for ﬁve out of six
vaccinated animals, stimulation indices were still greater for vacci-
nated animals compared to unvaccinated controls (Fig. 7B), during this
early time frame of infection, particularly at four weeks after the initial
challenge (P=0.02) (Fig. 7C). Positive proliferative responses during
the early 12 week time period after challenge were observed for only
two unvaccinated controls (Fig. 7B), which included the control
(32144)most resistant to challenge and capable of suppressing plasma
virus load to undetectable concentrations (Fig. 4B). Overall, these
observations suggested that both proliferative responses and IFN-γ
ELISPOT responses detected for vaccinated animals during early timepoints after challenge were vaccine-associated, rather than induced
strictly from active viral infection. SIV-speciﬁc proliferation responses
were detected once again for vaccinated and unvaccinated animals by
25 weeks after the initial challenge, with the exception of one
vaccinees (30359) that did not survive beyond 20 weeks after
challenge, and two unvaccinated macaques (31128, 32188), one of
which did not survive beyond 25 weeks after challenge. Of note,
proliferative responses detected on the day of challenge did not
correlate with control of virus load for individual vaccines (Fig. 4A).
Also of interest was the overall transient loss of proliferative responses
in vaccinated animals at 16 to 20 weeks after challenge; a time period
for which signiﬁcant differences in set point viral loads were also
diminished between vaccines and controls.
Antiviral antibody responses after challenge
Anamnestic antibody responses to SIVenv were noted by four
weeks after challenge for all vaccinated animals with the exception of
vaccinee 31541 that remained negative for plasma viral RNA after
multiple challenges (Fig. 7D), conﬁrming the virus load data. Positive
SIV Env antibody titers were found for three out of six unvaccinated
Fig. 7. SIV-speciﬁc T cell proliferative responses and SIV Env antibody responses in animals after challenge with SIVmac251. Virus-speciﬁc T cell proliferative responses are shown for
vaccinated (A) and unvaccinated control (B) animals over time after the initial challenge inoculation. Mean values for SI with standard error over time after challenge are shown for
both groups of animals (C). A SI of 2.5 or greater was considered positive (see dashed cut-line). Asterisks (⁎) positioned over values indicate a signiﬁcant difference between
vaccinated and SIV-infected unvaccinated controls as determined by a pair-wise comparison using a Mann–Whitney U test. Reciprocal endpoint titers for plasma antibodies against
native SIV Env are described for vaccinated (D) and unvaccinated control (E) animals over consecutive time points after challenge. Reciprocal endpoint titers N100 were considered
positive.
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by eight weeks after challenge (Fig. 7E). One unvaccinated control
animal (31128) failed to develop detectable antiviral plasma anti-
bodies when assayed by EIA (data not shown) or ConA ELISA (Fig. 7E),
as well as detectable SIV-speciﬁc IFN-γ ELISPOT or proliferative
responses, and did not survive beyond 25 weeks after challenge. By
12 weeks after infection Env antibody titers were comparable in
controls and vaccinees, with the exception of uninfected vaccine
31541 and the rapid progressor control 31128.
Quality of the cellular immune responses conferred by a rIL-15
expression plasmid to a SIV/CMVΔvif proviral DNA vaccine
To further examine changes in immunogenicity associatedwith co-
immunization of SIV/CMVΔvif DNA vaccine with an rIL-15 expression
plasmid, cellular immune responses induced by immunization with
SIV/CMVΔvif DNA alone, as previously described (Sparger et al., 2008)
were compared to those induced by co-immunization with SIV/
CMVΔvif and pNDgmsRRm-IL-15 plasmids. The SIV-speciﬁc IFN-γ
ELISPOT and proliferation assays used for both vaccine studies were
identical and conducted by the same laboratories. Although IFN-γ
ELISPOT responses to SIV Gag measured at early time points after
priming immunization were comparable for macaques vaccinated
with SIV/CMVΔvif DNA alone or with pNDgmsRRm-IL-15 plasmid,
responses after the ﬁrst and second booster immunizations were
signiﬁcantly greater for those animals vaccinated with a SIV/CMVΔvif
DNA vaccine that included the rIL-15 expression plasmid (Fig. 8A). In
contrast, SIV-speciﬁc T cell proliferative responses induced by the
priming immunization were signiﬁcantly improved by addition of the
rIL-15 expression plasmid, although improvement was not observedfor subsequent time points after booster immunizations (Fig. 8B).
These observations suggested that incorporation of rIL-15 into this
DNA vaccine regimen affected both CD4 and CD8 T cell responses
induced by a SIV/CMVΔvif DNA vaccine, although the effects on
CD8 responses were more long-lasting and striking. Alternatively,
effects on SIV-speciﬁc CD4 T cell responses may have appeared
short-lived due to IL-15-induced preferential emigration of antigen-
speciﬁc effector memory T cells from the periphery to tissues (Picker
et al., 2006).
Enhancement of SIV-speciﬁc CD8 T cell responses was also
substantiated by a subsequent study testing cryopreserved PBMC
samples harvested from animals vaccinated with SIV/CMVΔvif DNA
alone or with SIV/CMVΔvif and rIL-15 vaccine plasmids, by a cytokine
ﬂow cyotometry (CFC) assay testing for antigen-speciﬁc expression of
cytokines IL-2, TNF-α, IFN-γ, and the degranulation marker CD107a.
Based on ﬁndings for IFN-γ ELISPOT responses for these two vaccine
groups, frequencies of SIV capsid-speciﬁc T cells expressing either
single or multiple immune response markers at two weeks after a
second booster immunization were compared between the groups.
Frequencies of SIV-speciﬁc CD8 T cells expressing either the
degranulation marker CD107a, or TNF-α, and IFN-γ were appreciably
higher at this time point for macaques co-immunized with SIV/
CMVΔvif DNA plus rIL-15 compared to animals immunized with SIV/
CMVΔvif DNA alone (Fig. 8C), although the differences between mean
frequencies were not statistically signiﬁcant. More importantly,
evidence of polyfunctional CD8 T cells was shown for three out of
the six macaques co-immunized with SIV/CMVΔvif DNA plus rIL-15,
whereas polyfunctional responses were not observed for any animals
vaccinated with SIV/CMVΔvif DNA alone at this same time point after
booster immunizations (Fig. 8D). In contrast, notable differences in
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this same time point were not observed by this assay (data not
shown). These ﬁndings generated from themulti-parameter CFC assay
provided further evidence of an enhancement of vaccine-induced
CD8 T cell responses by the inclusion of rIL-15 as an immunomodu-
lator for this DNA vaccine approach.
Discussion
Our previous study testing immunogenicity and efﬁcacy of the SIV/
CMVΔvif proviral DNA vaccine, revealed that immunization with this
vif-deleted SIV provirus resulted in robust SIV-speciﬁc T cell prolif-
erative responses, but very weak antigen-speciﬁc CD8 T cell responses
(Sparger et al., 2008). Furthermore, suppression of virus after vaginal
challenge with SIVmac251 in vaccinated animals was transient and
apparent only for the ﬁrst eight weeks after challenge. Long-term
immunological protection is determined by both the quantity and
quality of memory T cells produced following initial antigen exposure
(Sarkar et al., 2008). As the number of memory T cells generated is
largely dependent on themagnitude of the primary immune response,
T cell-based vaccine strategies have focused on expanding antigen-
speciﬁc CD8 T cell populations. Earlier reports suggested promise for
the γc chain cytokine IL-15 as a vaccine adjuvant capable of promoting
ampliﬁcation and survival of antigen-speciﬁc CD8 T cells (Becker et al.,
2002; Oh et al., 2003; Surh and Sprent, 2002; Waldmann et al., 2001).
Accordingly, we hypothesized that co-immunization of the SIV/
CMVΔvif DNA vaccine with an optimized rIL-15 expression plasmid
would result in SIV-speciﬁc CD8 T cell responses augmented for both
frequency and polyfunctionality. We also hypothesized that rIL-15-
ampliﬁed antigen-speciﬁc CD8 T cell responses would result in
sustained suppression of virus loads after vaginal challenge with
pathogenic SIVmac251. Notably, ﬁndings from this current study
conﬁrmed that co-administration of a rIL-15 expression vector with
the SIV/CMVΔvif DNA vaccine was capable of substantial adjuvant
activity for the SIV/CMVΔvif DNA vaccine, based on results from both
immunogenicity and efﬁcacy studies.
One objective of this vaccine study was to examine SIV-speciﬁc
immune responses elicited by the SIV/CMVΔvif proviral DNA vaccine
regimen that incorporated a rIL-15 expression plasmid, and to
compare these responses to those elicited by immunization with
SIV/CMVΔvif DNA alone as reported previously (Sparger et al., 2008).
Given that IL-15 would be expected to primarily impact T cell
responses, similarities in antibody responses that were observed for
the two different vaccine protocols were not unexpected (data not
shown). Interestingly, robust vaccine-induced SIV-speciﬁc peripheral
T cell proliferative responses were comparable for SIV/CMVΔvif DNA-
vaccinated animals with, or without rIL-15 expression plasmid co-
inoculation. Similarly, assessment of SIV Gag-speciﬁc CD4 responses
tested at a single time point, two weeks after a second booster
immunization, by the multi-parameter CFC assay also revealed
comparable activity for animals immunized with SIV/CMVΔvif DNA
alone or with rIL-15 plasmid (data not shown).Fig. 8. Adjuvant effects on SIV-speciﬁc cellular immune responses conferred by IL-15. Mean v
priming immunization are shown for animals vaccinated with either SIV/CMVΔvif DNA alo
solid line denote booster immunization time points for animals vaccinated with SIV/CMVΔv
animals vaccinated with SIV/CMVΔvif DNA and pNDgmsRRm-IL-15 plasmids. Asterisks (⁎) p
two different vaccine groups, as determined by a pair-wise comparison using a Mann–Whi
responses (SI) over time after priming and booster immunizations are shown for animals
Frequencies of peripheral blood CD8 T cells expressing cytokines and a degranulation marke
after a second DNAvaccine booster immunization and compared between the two vaccine gr
for the two vaccine groups were not observed using a pair-wise comparison using a Mann–W
response markers, also at 2 weeks after a second DNA vaccine booster immunization, we
percentages of SIV Gag-speciﬁc CD8 T cells in each of 15 categories representing all possible c
all four markers (i.e., IL-2, IFN-γ, TNF-α and CD107) are indicated in red. Cells positive for thr
positive for a single function in light blue. Pie charts convert the total capsid-speciﬁc CD8 T
individual slices of the pie. Pie slices are color-coded to match the bar graphs. Numbers in
functional categories combined. ID denotes animal number and bar color for that particularIn contrast to ﬁndings for antigen-speciﬁc T cell proliferative and
CD4 responses, observations from this vaccine study suggested that
the principal IL-15 adjuvant effect was to increase function and
frequency of peripheral SIV-speciﬁc CD8 T cell responses. Although IL-
15 was shown by other investigators to enhance both CD4 and CD8
antigen-speciﬁc responses (Boyer et al., 2007; Oh et al., 2008; Picker et
al., 2006; Villinger et al., 2004), previous reports focused on IL-15-
mediated effects on antigen-speciﬁc CD8 T cell populations, demon-
strated increased antigen-speciﬁc CD8 T cell frequency, survival, and
independence from the requirement for CD4 T cell help (Boyer et al.,
2007; Halwani et al., 2008; Melchionda et al., 2005; Mueller et al.,
2005; Oh et al., 2008; Picker et al., 2006; Surh et al., 2006; Villinger et
al., 2004; Waldmann et al., 2001; Wallace et al., 2006; Zhang et al.,
2006). A comparison of SIV-speciﬁc IFN-γ ELISPOTafter immunization
with either SIV/CMVΔvif DNA alone, or with SIV/CMVΔvif DNA and
rIL-15, revealed signiﬁcant increases in ELISPOT responses to SIV Gag
for animals immunized with vaccine including rIL-15 expression
plasmid, particularly for time-points after the second booster
immunization. A trend towards increased frequencies of SIV Gag-
speciﬁc CD8 T cells capable of expressing either IFN-γ, TNF-α, or
CD107a, was also observed at this same time point. Moreover, animals
immunized with an SIV/CMVΔvif DNA vaccine that included rIL-15,
were more likely to develop polyfunctional CD8 T cell responses, as
shown by data from the CFC assay. These data revealed that at least
half of the animals co-immunized with SIV/CMVΔvif and rIL-15 DNA,
demonstrated polyfunctional SIV Gag-speciﬁc CD8 T cells capable of
expressing two to three cytokines including IFN-γ, TNF-α, and IL-2, as
well as a degranulation marker CD107a. Conversely, none of the
animals vaccinated with SIV/CMVΔvif alone exhibited SIV Gag-
speciﬁc polyfunctional CD8 T cell responses. Recent reports have
shown that polyfunctional antigen-speciﬁc CD8 and CD4 T cell
responses may be important correlates for control of HIV infection
and for vaccine efﬁcacy (Almeida et al., 2007; Duvall et al., 2008;
Genescà et al., 2007; Harari et al., 2007; Makedonas and Betts, 2006;
Precopio et al., 2007). Frequencies of SIV Gag-speciﬁc CD8 T cells
measured by these CFC assays and observed for animals immunized
with SIV/CMVΔvif and rIL-15 DNA were modest compared to values
observed for SIV or HIV-infection or combination immunization
approaches that including both DNA and viral vector modalities.
However, these responses were very signiﬁcant compared to those
generated after immunizationwith HIV-1 and SIV DNA vaccines alone
(Catanzaro et al., 2007; Kwissa et al., 2007; Tavel et al., 2007).
Accordingly, these ﬁndings from the CFC studies provide strong
evidence of IL-15′s capacity to improve both the quality and quantity
of antigen-speciﬁc CD8 T cell responses induced by a SIV/CMVΔvif
DNA vaccine.
The possibility that IL-15 may have increased viral gene expression
or virus replication from the provirus vaccine plasmid via activation of
the transduced target cells cannot be ruled out and warrants
consideration. Reports describing investigation of IL-15 as a ther-
apeutic in SIV-infected animals have generated conﬂicting observa-
tions regarding the beneﬁts of such treatment with this cytokine. Twoalues for SIV-speciﬁc IFN-γ ELISPOT (SFC) to SIV Gag with standard error over time after
ne, or with both SIV/CMVΔvif and pNDgmsRRm-IL-15 plasmid DNA (A). Arrows with a
if DNA alone. Arrows with a dashed line denote booster immunization time points for
ositioned over values indicate a signiﬁcant difference between values measured for the
tney U test. Similarly, mean values for peripheral blood SIV-speciﬁc T cell proliferation
vaccinated with SIV/CMVΔvif DNA alone or also with pNDgmsRRm-IL-15 plasmid (B).
r CD107a after exposure to a SIV capsid peptide pool were measured by CFC at 2 weeks
oups (C). Signiﬁcant differences between frequencies for each immune response marker
hitney U test. Frequencies of peripheral blood CD8 T cells expressing multiple immune
re compared between the two vaccine groups (D). Bar graphs on the left show the
ombinations of the cytokines and the degranulation marker analyzed. Cells positive for
ee markers are shown in dark blue; those positive for two functions in green; and those
-cell response in each macaque to 100%, with 4-, 3-, 2-, and 1-function cells shown as
the center of each pie indicate the total capsid-speciﬁc CD8 T-cell response, with all
animal represented on the graph.
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cell populations, without adverse effects on virus load (Mueller et al.,
2005; Picker et al., 2006). Other reports described adverse effects on
disease and increased virus loads when IL-15 was tested as a
therapeutic agent during acute SIV infection (Mueller et al., 2008),
or was used as an adjuvant for a therapeutic vaccine for SIV infection
(Hryniewicz et al., 2007). Both reports described signiﬁcant prolifera-
tion or activation of the memory effector CD4 T cell subset associated
with IL-15 treatment that possibly caused, or at least contributed to
the enhanced virus loads observed with use of this cytokine in a
therapeutic regimen. However, testing of IL-15 as a therapeutic during
infection as described by these reports, is quite different from use of
an IL-15 expression plasmid as an adjuvant for a prophylactic DNA
vaccine. The CMV/SIVΔvif DNA vaccine is not an absolutely defective
provirus; replication of virus generated from this provirus is possible
only in cells that do not express critical APOBEC3 proteins including
APOBEC3F and APOBEC3G (Chiu and Greene, 2008). These cellular
restriction factors eliminate most, if not all of the viable target cell
populations capable of propagating this viral mutant in vivo. There-
fore, the nature of the pre-integration infectivity defect conferred by a
vif deletion generates an essentially single cycle virus, and rules out
the likelihood of actual increased virus replication or virion infectivity
induced by IL-15, regardless of CD4 Tcell or immune activation events.
Importantly, real-time PCR assays for peripheral blood virus load,
including plasma viral RNA and PBMC viral DNA, did not detect viral
nucleic acid after multiple proviral DNA inoculations with IL-15 for the
current study (data not shown), similar to previous ﬁndings with
multiple inoculations of proviral DNA without IL-15 (Sparger et al.,
2008). Furthermore, evidence of increased virus expression was not
supported by increased antiviral antibody titers after immunization
when compared to vaccination with CMV/SIVΔvif alone. Thus,
augmented CD8 T cell response most likely resulted from immuno-
modulatory properties associated with the rIL-15, rather than
increased proviral DNA vaccine expression.
Another critical objective for this vaccine study was to test the
efﬁcacy of a SIV/CMVΔvif proviral DNA vaccine approach that
incorporated rIL-15 plasmid as a cytokine adjuvant. Vaccinated and
unvaccinated control macaques were challenged with highly
pathogenic SIVmac251 by the IVAG route using a previously
described multiple low dose protocol (Ma et al., 2004). Although
virus load kinetics were comparable for vaccinated and unvaccinated
controls, peak plasma virus loads and more importantly viral load set
points, were signiﬁcantly lower for vaccinated animals compared to
unvaccinated controls for an extended period of time, a result that
has been challenging for many vaccine studies using SIVma251 as
the challenge isolate (Feinberg and Moore, 2002; Watkins et al.,
2008). Moreover, this control of viremia in vaccinated animals
correlated with moderate SIV IFN-γ ELISPOT and T cell proliferative
responses that were absent in unvaccinated controls during the ﬁrst
twelve weeks after the initial challenge inoculation. These observa-
tions suggest that vaccine-induced cellular immune responses were
preserved during the acute phase of infection in the face of peak
virus replication and may have contributed to suppression of virus
loads in vaccinated animals. Plotting of SIV Gag IFN-γ ELISPOT
responses against virus loads over the ﬁrst 20 weeks after challenge
suggested an association between T cell responses and host control
of virus replication although a signiﬁcant correlation was not
detected. These data therefore lend rationale for the inclusion of a
T cell-targeted immunomodulator such as IL-15 for HIV-1 prophy-
lactic immunization strategies.
A comparison of vaccine efﬁcacy generated by co-immunization
with CMV/SIVΔvif DNA and rIL-15 as an adjuvant with efﬁcacy
afforded by immunization with CMV/SIVΔvif proviral DNA alone
(Sparger et al., 2008), was somewhat complicated by the use of two
different SIVmac251 IVAG challenge protocols for each vaccine study.
Interestingly, virus load kinetics for the unvaccinated controlschallenged with multiple low doses in the current study were
comparable to those for unvaccinated controls receiving a single day
high dose vaginal challenge in our previous CMV/SIVΔvif DNA
vaccine study (data not shown). However, a decreased median
survival for unvaccinated controls was associated with the high dose
IVAG challenge used in the previous study; this difference in
responses to challenge by the unvaccinated controls precluded a
direct comparison of outcomes for animals vaccinated with either
CMV/SIVΔvif DNA alone or with rIL-15. Thus, while we are not
proposing a direct comparison of challenge outcomes between both
studies, our current data suggest improvement in vaccine-induced
cellular immune responses, conservation of these responses after
infection, and antiviral control upon addition of IL-15 to the CMV/
SIVΔvif DNA vaccine. These ﬁndings support other recent reports
showing improved efﬁcacy elicited by addition of a rIL-15 expression
plasmid to a SHIV DNA vaccine (Boyer et al., 2007; Yin et al., 2008),
but conﬂict with other recent studies showing no efﬁcacy for
different SIV DNA vaccine approaches incorporating a rIL-15 expres-
sion plasmid when tested against either SHIV89.6P or SIVmac251
challenges (Chong et al., 2007; Demberg et al., 2008). However,
differences in multiple variables between these studies and our
current study including the speciﬁc SIV DNA vaccine tested, IL-15
plasmid dose, DNA delivery schedule, sites for IL-15 plasmid delivery,
and challenge routes, may be responsible for the dissimilarity in
challenge outcomes. Clearly, future studies with larger numbers of
animals and immune response assays that address antigen-speciﬁc
responses within different T cell memory populations as well as
expression of additional T cell functions, will be needed to more
clearly deﬁne immune correlates for this vaccine approach based on
the combination of vif-deleted proviral DNA and IL-15 expression
plasmid. Regardless, our current ﬁndings illustrate the potential for
this cytokine to modulate immunogenicity and efﬁcacy of a
prophylactic anti-SIV DNA vaccine. Overall, these ﬁndings reveal
important implications for the design of future HIV-1 vaccines and
support further exploration of IL-15 as an immunomodulator for a
prophylactic HIV-1 vaccine.
Materials and methods
Vaccine plasmids
The SIV/CMVΔvif vaccine plasmid containing a vif-deleted SIV-
mac239 proviral DNA genome and a hybrid SIVmac239 LTR encoding
the enhancer region of the human cytomegalovirus (CMV) immediate
early (IE) gene promoter, was previously described (Sparger et al.,
2008; Zou and Luciw, 1996). All SIV/CMVΔvif plasmid preparations
were tested for stability by proviral plasmid transfection of 293 T cells
followed by assay of transfected-cell culture supernatants for virus
particles and for infectivity for MM221 cells, a rhesus T cell line
(provided by Ronald Desrosiers, New England Primate Research
Center) as previously described (Sparger et al., 2008).
Two approaches were taken to generate a rIL-15 expression
plasmid for testing as a cytokine adjuvant for the SIV/CMVΔvif
proviral DNA vaccine. One plasmid designated pNDRRm-IL-15, was
constructed by insertion of Mamu (rhesus macaque) IL-15 sequence
including the long native 48 amino acid leader sequence (Villinger et
al., 1995), into expression vector pND (kindly provided by Dr. G
Rhodes, University of California Davis) (Lena et al., 2002). The insert of
a second rhesus rIL-15 pND plasmid (pNDgmsRRm-IL-15) contained
the 17 amino acid Mamu GM-CSF leader sequence fused to the mature
Mamu IL-15 coding sequence to replace the native IL-15 leader
sequence. Both rIL-15 expression plasmids were conﬁrmed by
nucleotide sequencing and assayed for activity as described below.
All vaccine plasmid DNA was prepared by standard alkaline lysis and
centrifugation to equilibrium twice in cesium chloride-ethidium
bromide gradients.
119R.A. Dubie et al. / Virology 386 (2009) 109–121In vitro analysis of the rhIL-15 expression plasmid
Plasmids pNDRRm-IL-15 and pNDgmsRRm-IL-15 were tested for
production of cell-free IL-15 by transfection of COS-7 and 293T cells
using DOTAP (Roche) according to the manufacturer's instructions.
Transfected-cell culture supernatants were harvested at two, four, and
six days after transfection, passed through a 0.22 μ ﬁlter and tested by
a commercial human IL-15 antigen-capture ELISA (Invitrogen, Bio-
source) that is cross-reactive with Mamu IL-15. Supernatants from
cells transfected with IL-15 expression plasmids were also tested for
IL-15 biological activity using the IL-2/15-dependent HT-2 cell line as
previously described (Villinger et al., 1995).
Vaccination and challenge
Adult colony-bred, multiparous female rhesus macaques (Macaca
mulatta) were housed at the California National Primate Research
Center (CNPRC) in accordance with the regulations of the American
Association for Accreditation of Laboratory Animal Care standards.
All animals were negative for antibodies to HIV-2, SIV, type D
retrovirus, and simian T-cell lymphotropic virus type 1 prior to the
start of the study. Tissue typing revealed that all animals were
negative for the major histocompatibility complex (MHC) class I
allele Mamu-A⁎01, whereas one animal (30889) within the vacci-
nated group was positive for MHC class I allele Mamu-B⁎17. Animals
were examined at regular time intervals for body weight, lympha-
denopathy, splenomegaly, and opportunistic infections. Criteria for
euthanasia included three or more of the following: a greater than
10% loss of body weight, persistent infections unresponsive to
therapy, chronic diarrhea unresponsive to therapy, persistent and
marked hematologic abnormalities, and persistent dehydration
without ﬂuid supplementation.
Six female macaques were immunized by co-inoculation of 1 mg
SIV/CMVΔvif and 1 mg pNDgmsRRm-IL-15 distributed between in-
tramuscular (IM) and intradermal (ID) routes of delivery. Speciﬁcally,
each animal received 600 μg of SIV/CMVΔvif plasmid DNA and
600 μg of pNDgmsRRm-IL-15 plasmid as two separate IM injections.
Each animal also received 400 μg of SIV/CMVΔvif plasmid DNA and
400 μg of pNDgmsRRm-IL-15 plasmid via separate ID inoculations.
Animals received booster inoculations of vaccine plasmids in iden-
tical concentrations and by the same routes at 8 and 20 weeks
after the priming immunization. At 30 weeks after priming immu-
nization, a multiple low dose SIVmac251 challenge by the vaginal
route was performed weekly as previously described (Ma et al.,
2004). Brieﬂy, each individual animal received two, 1 ml inoculations
of 103 TCID50 of SIVmac251 intravaginally within a four hour time
period over one day, at weekly intervals until that animal demon-
strated a plasma viremia for two consecutive weeks, or until all
control animals tested positive for plasma SIV RNA. Peripheral blood
was collected at two to four week intervals after immunization and
challenge, for assay of virus-speciﬁc immune responses and hema-
tologic alterations by complete blood cell count and CD4/CD8 subset
analysis.
Virus load determination
A previously described quantitative real-time RT TaqMan PCR
assay (Applied Biosystems, Foster City, CA) (Leutenegger et al., 2001)
with a detection limit of 100 RNA copies/ml, was used for measure-
ment of plasma SIV RNA concentrations. The presence of PBMC-
associated SIV proviral DNAwas also tested using previously described
protocols for DNA extraction (Sparger et al., 2008) and a real-time
TaqMan PCR assay that included assay for rhesus IL-2 as a house-
keeping gene for all reactions (Leutenegger et al., 2001). All PCR
reactions were performed in an ABI PRISM Sequence Detector
(Applied Biosystems).Antiviral antibody detection
Plasma SIV-speciﬁc antibody was assayed by a commercial HIV-1/
HIV-2 ELISA (Genetic Systems Corporation, Redmond, WA) following
the manufacturer's instructions. Plasma antibody to native SIV
envelope proteins was assayed by a highly sensitive Con-A ELISA as
previously described (Cole et al., 1997) with the following modiﬁca-
tion. ELISA plates were coated with a four-fold increase in concentra-
tion of SIVmac239 virus to enhance the sensitivity of this ELISA.
IFN-γ ELISPOT assay
SIV-speciﬁc IFN-γ-producing PBMC were quantitated from cryo-
preserved PBMC by a previously described recombinant vaccinia
virus-based ELISPOT assay after immunization and virus challenge
(Larsson et al., 1999; Shacklett et al., 2002; Sparger et al., 2008).
Antigens used for this IFN-γ ELISPOT included recombinant vaccinia
viruses expressing SIVmac251 Gag (vAbT252), Env (vAbT2531), Pol
(vAbt258), and Nef, or control r-VV (Therion Biological, Cambridge,
MA). Spot-forming cells (SFC) detected on a commercial 96-well
ELISPOT plate (U-Cytech, Utrecht, The Netherlands) coated with
monoclonal antibody speciﬁc for macaque IFN-γ were counted using
an automated ELISPOT reader (AID, Automimmun Diagnostika, Cell
Technology Inc., Columbia MD). Results were presented as SFC per 106
cells after subtraction of background SFC measured for control
vaccinia virus and values greater than 50 SFC per 106 cells, were
considered positive.
SIV-speciﬁc T cell proliferation assay
SIV-speciﬁc T cell proliferative responses were measured using a
previously described traditional 3H-labeled thymidine incorporation
assay (Abel et al., 2003; McChesney et al., 1998). SIV inactivated by
treatment with aldrithiol-2 (AT-2) (kindly provided by Jeff Lifson,
Laboratory of Retroviral Pathogenesis, SAIC Frederick, Bethesda, MD)
at concentrations of 12.5 and 125 ng of SIV p27Gag/well, provided the
viral antigen used for this T cell proliferation assay. The stimulation
index was calculated as the ratio between counts per minute (CPM)
with antigen and CPM in the absence of antigen and a SI of 2.5 or
greater was considered positive. All proliferation assays were
performed by the CNPRC Immunology Core.
Cytokine ﬂow cytometry
SIV-speciﬁc T cell responses after vaccination were examined for
phenotype and multiple functions by a multiparameter cytokine ﬂow
cytometry assay. All antibodies were purchased from BD Biosciences
and titrated prior to use. The LIVE/DEAD Aqua Fixable Cell Stain Kit
was purchased from Invitrogen/Molecular Probes. Cryopreserved
rhesus macaque PBMC prepared from vaccinated animals from the
current study and a previous SIV/CMVΔvif DNA vaccine study
described below (Sparger et al., 2008), were thawed and rested
overnight in RPMI 1640 containing 20% FBS at 37C with 5% CO2. PBMC
were tested for SIV Gag responses using a pool of SIV capsid 15-mer
peptides overlapping by 11 amino acids (NIH AIDS Research and
Reference Reagent Program). Stimulation with mitogen SEB (100 μg/
ml) and DMSO (1.5%) were used as positive and negative controls,
respectively. During the 6-hour stimulation in R15 (15% FBS) media,
CD49d (clone L25) and CD28 (clone L293) antibodies (1 μg/ml),
Brefeldin A (5 μg/μl, Sigma), GolgiStop (1 μl, BD Biosciences) and
CD107a PE-Cy7 antibody (clone H4A3) were included. Cells were
harvested, washed, and further processed using Cytoﬁx/Cytoperm Kit
(BD Biosciences) according to manufacturers recommendations with
the following modiﬁcations. Cells were re-suspended in 0.5 mM EDTA
and stained for cell surface markers with labeled antibodies CD4-FITC
(clone L200), CD8-APC (clone SK1), CD3-PacBlue (clone SP34-2), and
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ﬁxed and permeabilized using cytoﬁx/cytoperm reagent from the
commercial kit. Cells were then stained for intracellular cytokine
expression with monoclonal antibodies reactive to TNF-α-Alexa700
(clone MAb11), INF-γ-PE-Cy5 (clone B27), and IL-2-PE (clone MQ1-
17H12). Data from 100,000 lymphocyte-gated events were acquired
using a LSRII ﬂow cytometer (BD Biosciences) and analyzed using
FlowJo software (Treestar, Inc). Data was reported after subtraction of
values for DMSO treatments alone. Responses with frequencies equal
to or greater than 0.02% were considered positive for single and
multiple markers. Software programs SPICE v4.15 and PESTLE v1.5.2
(provided by Mario Roederer, Vaccine Research Center, NIAID, NIH)
were used to characterize polyfunctional T cell responses and to
generate pie charts representative of individual animal's CD8 T cell
responses.
Comparison of immunogenicity afforded by an IL-15 expression plasmid
to a vif-deleted SIVmac239 proviral DNA vaccine
Cellular immune responses measured by SIV-speciﬁc IFN-γ
ELISPOT, proliferation, and CFC assays were compared for vaccine
groups immunized with SIV/CMVΔvif proviral DNA alone as
previously described (Sparger et al., 2008), or co-immunized with
SIV/CMVΔvif and pNDRRm-IL-15 plasmids as described for the
current study. For the previously reported SIV/CMVΔvif DNA vaccine
study, a group of six female rhesus macaques was immunized with
SIV/CMVΔvif DNA plasmid at similar concentrations (1 mg) dis-
tributed between ID and IM routes as described for the current study.
The boosting schedule used for this previous study was slightly
different with a ﬁrst booster SIV/CMVΔvif DNA inoculation adminis-
tered at 6, instead of 8, weeks after priming immunization, and a
second booster SIV/CMVΔvif DNA at 22, instead of 20, weeks after
priming immunization. SIV/CMVΔvif DNA plasmid concentrations
and routes of delivery for booster immunizations were identical to
those described above for SIV/CMVΔvif DNA co-immunized with
pNDgmsRRm-IL-15 plasmid.
Statistics
A nonlinear mixed-effects model based on an exponential function
was ﬁtted to log RNA values using software SAS version 9, with RNA
recorded from the ﬁrst observation of peak plasma viral RNA, to compare
virus loads between vaccinated and unvaccinated animals after challenge.
Virus loads at speciﬁc time points were also compared using the Mann–
Whitney U test (GraphPad Prism). Other statistical analysis comparing
values for SIV-speciﬁc IFN-γ ELISPOT, T cell proliferation responses, and
CD8Tcell frequencies for single immune responsemarkers at speciﬁc time
points, was also based on theMann–WhitneyU test. Correlation between
IFN-γ ELISPOT responses and virus loads after challenge was assayed by
the Spearman rank-order correlation test (GraphPad Prism). P values
b0.05 were considered signiﬁcant.
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